A groundbreaking surgical technique using high-pressure water jets is showing promise in preserving ejaculatory function for men undergoing surgery for an enlarged prostate. This innovative procedure, known as Aquablation, has been found to offer comparable outcomes to traditional laser surgeries while potentially reducing adverse side effects such as retrograde ejaculation and urinary incontinence.

Researchers from the University of Bonn led a multi-national trial involving participants from Germany and the UK, focusing on the safety and efficacy of Aquablation for larger prostates. The study compared this method with standard laser treatments like Holmium laser prostate surgery (HoLEP) and Thulium laser enucleation of the prostate (ThuLEP). Results indicated that only 15% of sexually active men in the Aquablation group experienced retrograde ejaculation, compared to 77% in the laser group. Additionally, urinary incontinence rates were lower at 9% versus 20% respectively. These findings suggest that Aquablation could provide a viable alternative for patients seeking to maintain their quality of life post-surgery.

Advancements in medical technology continue to enhance treatment options for common health conditions, offering hope for improved patient outcomes. According to Professor Manuel Ritter, head of urology at the University Hospital Bonn, many men tolerate symptoms of benign prostatic hyperplasia (BPH) without realizing there are effective solutions available. With its ability to preserve sexual function and reduce recovery complications, Aquablation not only alleviates urinary issues but also addresses concerns about sexual health. Furthermore, its accessibility due to a less steep learning curve for surgeons could lead to shorter waiting times for necessary procedures, ultimately benefiting countless individuals globally.